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Abstract
Pancreatic cancer is an increasing cause of cancer related death worldwide. KRAS is the
dominant oncogene in this cancer type and molecular rationale would indicate, that inhibi-
tors of the downstream target MEK could be appropriate targeted agents, but clinical trials
have failed so far to achieve statistically significant benefit in unselected patients. We aimed
to identify predictive molecular biomarkers that can help to define subgroups where MEK
inhibitors might be beneficial alone or in combination. Next-generation sequencing data of
50 genes in three pancreatic cancer cell lines (MiaPaCa2, BxPC3 and Panc1) were ana-
lyzed and compared to the molecular profile of 138 clinical pancreatic cancer samples to
identify the molecular subtypes of pancreatic cancer these cell lines represent. Luminescent
cell viability assay was used to determine the sensitivity of cell lines to kinase inhibitors.
Western blot was used to analyze the pathway activity of the examined cell lines. According
to our cell viability and pathway activity data on these model cell lines only cells harboring
the rare G12C KRAS mutation and low EGFR expression are sensitive to single MEK inhibi-
tor (trametinib) treatment. The common G12D KRAS mutation leads to elevated baseline
Akt activity, thus treatment with single MEK inhibitors fails. However, combination of MEK
and Akt inhibitors are synergistic in this case. In case of wild-type KRAS and high EGFR
expression MEK inhibitor induced Akt phosphorylation leads to trametinib resistance which
necessitates for MEK and EGFR or Akt inhibitor combination treatment. In all we provide
strong preclinical rational and possible molecular mechanism to revisit MEK inhibitor ther-
apy in pancreatic cancer in both monotherapy and combination, based on molecular profile
analysis of pancreatic cancer samples and cell lines. According to our most remarkable find-
ing, a small subgroup of patients with G12C KRAS mutation may still benefit from MEK
inhibitor monotherapy.
Introduction
Despite the recent success of targeted therapies treating several tumor types, pancreatic cancer
still has very poor prognosis. According to the data of Globocan 2012, pancreatic cancer is
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responsible for 331000 deaths per year worldwide and has a mortality: incidence ratio of 0.98
[1]. A projection of cancer deaths in the United States to 2030 ranks this cancer type to the sec-
ond place, just behind lung cancer [2].
The relatively few types and rarity of alarming symptoms lead to diagnosis at an advanced
stage, which makes surgical treatment often impossible, or insufficient [3], thus only a well-
chosen systemic therapy could improve the chances of survival.
The genetic landscape of pancreatic cancer is well characterized [4, 5] and dominated by
four “mountains of cancer genes”: KRAS (71%), TP53 (49%), CDKN2A (22%) and SMAD4
(20%) [4, 6, 7]. Nonetheless FDA approved only three new treatments in the last 20 years for
pancreatic cancer (gemcitabine, erlotinib, nab-paclitaxel), of which the only targeted agent is
the EGFR inhibitor erlotinib.
The biggest challenge is the high rate of KRAS mutations, whose direct inhibition -despite
all efforts- is still difficult. The use of potent indirect, downstream inhibitors such as MEK
inhibitors made no or not significant improvement in overall and progression-free survival,
even if the patients with mutant KRAS bearing tumors were analyzed separately [8, 9].
Prahallad and colleagues proved the existence of a feedback loop resulting in the activation
of the EGFR/PI3K/Akt pathway when using BRAF inhibitors in colon cancers cell lines [10].
This mechanism was also confirmed in pancreatic cancer cell lines. It was also revealed that
MEK inhibitors and PI3K inhibitors have a synergistic effect in certain cases [11, 12]. However
the underlying molecular patterns of sensitive and resistant tumors are not clear therefore the
prediction of synergetic effect is currently not possible.
The routine molecular profiling of tumors in clinical setting with targeted hotspot next gen-
eration sequencing (NGS) panels is more and more common in precision oncology programs
of large oncology centers. The results are interpreted by molecular tumor boards to refer
patients to targeted clinical trial or indicate target based off-label therapies.
The aim of our research was to analyze if there is a subtype of pancreatic cancer patients
based on detailed molecular profile available in clinical settings, which would benefit from
MEK inhibitors in monotherapy or in combination with other targeted therapies in clinical tri-
als or off label indications, and to provide scientific rationale to initiate new trials with MEK
inhibitors in specific molecular subtypes of pancreatic cancers. We used molecularly profiled
pancreatic cell lines as relevant in vitro pharmacological models to examine the activated sig-
naling pathways in the presence of different genetic alterations, than test their different sensi-
tivity to MEK inhibitors alone and in combination with other kinase inhibitor combination
therapies. Our main question was whether we could predict the efficacy of mono- or combina-
tion therapy in certain subgroups of pancreatic cancer patients based on their kinase muta-
tion/expression pattern and if there is a patient subgroup which yet benefits from MEK
inhibitors at all.
Methods
Data collection
In our retrospective analysis archived Sanger sequencing and next generation sequencing
(NGS) data of one hundred thirty-eight pancreas tumors were collected anonymously from
the database of the molecular diagnostic laboratory of Oncompass Medicine Ltd. and used for
statistical analysis. In the database, fifty oncogenes and tumor suppressor genes (Ion Ampliseq
Cancer HotSpot panel v2) were analyzed in 114 patients by next generation sequencing (Ion-
Torrent platform) and different exons of 13 oncogenes were analyzed in 24 patients by Sanger
sequencing. In case of NGS biopsies containing tumor cells over 10% were used and coverage
between 1000-fold and 1500-fold was achieved. Variants were analyzed using databases to
MEK inhibitors in pancreatic cancers
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distinguish somatic and hereditary alterations, no normal tissue or blood samples were used.
All the sequencing reactions were carried out between 2012 and 2016. Informed consent was
obtained from all patients and the anonymized statistical use of sequence data was approved
by the National Medical Research Council which serves as the national ethical review commit-
tee in Hungary.
DNA extraction and next generation sequencing of cancer cell lines
The same method was used for the next generation sequencing of three cell lines as in case of
formalin-fixed, paraffin-embedded (FFPE) tumor samples. About 500.000 live, cultured cancer
cells were harvested for DNA extraction (QIAamp DNA FFPE Tissue Kit, Qiagen, Cat. No.
56404). DNA library were was prepared using Ion AmpliSeq™ Library Kit 2.0 (Thermo Fisher
Scientific, Cat. No. 4475345) according to the manufacturer’s instruction. 207 gene fragments
were amplified by multiplex PCR (Ion AmpliSeq Cancer Hotspot Panel v2, Thermo Fisher Sci-
entific, Cat No. 4475346). The target sequences were partially digested followed by barcode
adapter ligation using Ion Xpress™ Barcode Adapters. Then the libraries were purified using
AgencourtTM AMPureTM XP Reagent for the next step of clonal amplification. The pure DNA
library was eluted with DNase free water, which does not disturb any downstream methods.
Purified DNA library were quantified using Agilent Bioanalyzer DNA chip (High Sensitivity
DNA Kit, Kromat Kft, Cat No. 5067–4626) and sequenced on Ion 318 Chip by Ion PGM
equipment in the laboratory of Seqomics Kft (Mo´rahalom, Hungary). The average depth cov-
erage of the amplicons was about 200 000 reads per sample. Variants detected in the libraries
were listed in VCF (Variant Call Format) files then annotated and analyzed by the company’s
own software. Briefly, union of two VCF files are used as the input of the software, as two par-
allel NGS takes place from the same tumor sample. These files contain raw data from the
sequencing: the detected variants on genomic level, the corresponding quality values, details
about the used settings and previous filtering methods. The software annotates the exonic vari-
ants on coding DNA and protein level and calculates an artificial confidence score based on
selected important quality measures. The final mutation list was evaluated by considering qual-
ity scores and filtering out false positive variants.
Cell culturing
Pancreas adenocarcinoma cell lines MiaPaCa2, BxPC3 and Panc1 obtained from ATCC were
cultured in DMEM supplemented with 10% (V/V) fetal bovine serum (FBS, Lonza), 2.5%
horse serum (HS, Lonza) and 1% antibiotic mix (MZ, MycoZap Plus-CL, Lonza), RPMI sup-
plemented with 10% FBS and 1% MZ and DMEM supplemented with 10% FBS and 1% MZ
respectively in humidified atmosphere of 37˚C and 5% CO2.
Kinase inhibitors
Trametinib, afatinib, erlotinib were purchased from Selleckchem (Selleckchem, Munich,
Germany), PD0325901, refametinib (RDEA119), triciribine (MK2206) and selumetinib
(AZD6244) were purchased from ChemieTek (Indianapolis, IN, USA).
Cell viability assay and drug synergism
Cell viability was measured with the CellTiter-Glo Luminescent Cell Viability assay (Promega).
1000 per well of the cultured cell lines were seeded into white 96-well plates. Cell lines were left
overnight to attach, then treated with decreasing concentrations of trametinib, afatinib, triciri-
bine and the combination of trametinib+afatinib and trametinib+triciribine in duplicates. The
MEK inhibitors in pancreatic cancers
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final DMSO concentration was 0.2% or less. 72 hours after treatment, appropriate amount of
CellTiter-Glo Reagent was added to the cell culture medium in each well. After about 2 min-
utes shaking, plates were incubated in dark at room temperature for 10 minutes. Luminescent
signal was recorded by BioTek Synergy 2 Multi-Mode Microplate Reader. Each experiment
was repeated at least three times.
Potential drug synergism was confirmed and combination index at different effective doses
(ED) was calculated with Compusyn software, which is based on the Median-Effect Principle
and the Combination Index-Isobologram Theorem [13]. Combination indexes generated by
Compusyn indicate drug synergism under 1 and additive effect between 0.75 and 1.25 [14]. In
this research combination indexes were calculated in a constant concentration ratio of the
drugs used.
Western blot analysis
Cells were grown to 90% confluence in 6 well plates and were treated with 10 nM trametinib
in complete medium. After treatment, cells were washed with ice-cold PBS and lysed in lysis
buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1% (V/V) NP-40, 2 mM EDTA, 2 mM EGTA, 50
mM NaF, 1 mM dithiothreitol, 1 mM sodium-ortovanadate and protease inhibitor cocktail
(Calbiochem) for 30 minutes on ice. Lysates were centrifuged with 13 000 g at 4˚C for 15 min-
utes and supernant was used for analysis. 10 μg protein samples were subjected to SDS-PAGE
and electrotransferred to polyvinylidene-difluoride (PVDF) membranes. Membranes were
incubated with the diluted primary antibodies [(total EGFR (clone D38B1, Cat. No. 4267, dilu-
tion 1:4000), phospho-Tyr1068 EGFR (clone D7A5, Cat. No. 3777, dilution 1:1000), total Akt
(clone 40D4, Cat. No. 2920, dilution 1:4000), phospho-Ser473 Akt (clone D9E, Cat. No. 4060,
dilution 1:2000), total ERK 1/2 (clone 3A7, Cat. No. 9107, dilution 1:2000), phospho-Thr202/
Tyr204 ERK 1/2 (clone D13.14.4E, Cat. No. 4370, dilution 1:8000) monoclonal antibodies
were purchased from Cell Signaling Technology (Danvers, MA, USA) and α-tubulin (clone
DM1A, Cat. No. T9026, dilution 1:40000) monoclonal antibody was purchased from Sigma-
Aldrich (St. Louis, MO, USA)] at 4˚C overnight, and with horse radish peroxidase (HRP) con-
jugated secondary antibodies for 1 h at room temperature. Bands were visualized by Enhanced
Chemiluminescence (ECL) detection system (Perkin Elmer, Waltham, MA, USA) and quanti-
fied by ImageJ v1.48 software. Every experiment was carried out at least 3 times.
Results
Based on next generation sequencing of 50 genes the molecular profile
of MiaPaCa2, BxPC3 and Panc1 cell lines together represent more than
the third of pancreatic cancer types
We found the mutation of KRAS in 76.8% of the cases. In 68.9% of the examined tumors, the
mutation affected the hotspot at codon 12. Other alterations were found in codon 19 (0.7%),
codon 13 (0.7%) and codon 61 (6.5%) the remaining about 23% of the patients had tumors
with wild type KRAS. KRAS G12D mutation represented the highest percentage (31.2%) and
G12C change was relatively rare (1.5%). The rest of codon 12 mutation divided between G12V
(21.7%) and G12R (14.5%).
Mutations (missense, nonsense and frameshift) found with NGS of the examined genes and
their combined presence is shown in (Fig 1). Based on the next generation sequencing results
of the 3 cell lines the following mutations were found: MiaPaCa2 (homozygote mutations in
KRAS G12C, TP53 R248W, NOTCH1 L2457V), Panc1 (homozygote mutation in TP53
R273H and heterozygote mutation in KRAS G12D) and BxPC3 (homozygote mutation in
MEK inhibitors in pancreatic cancers
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TP53 Y220C and KDR Q472H). According to the four most relevant genes (based on COS-
MIC database) KRAS, TP53, CDKN2A and SMAD4, our in vitro tumor model covers the
mutational status of 51/114 (44.4%) pancreas tumor biopsies. If we only take KRAS mutations
into consideration MiaPaCa2 (1.5%), Panc1 (31.2%) and BxPC3 (23%) represent more than
the half of investigated pancreatic cancers (Fig 1).
It should be noted, that like BxPC3, 42 of the sequenced 114 tumors harbored Q472H
mutation in KDR gene. Q472H is frequently observed in melanomas as a germline mutation
being associated with increased KDR phosphorylation. While the mutation of NOTCH1 [15]
in MiaPaCa2 is not lying within any functional domain and has no known effect on its activity,
we didn’t deal with it. CDKN2A and SMAD4 mutations were found in less cases than indi-
cated in COSMIC database, but this can be due to the method, because only the most relevant
amplicons of these tumor suppressor genes were sequenced. The full data of the examined
amplicons can be found on the manufacturer’s homepage (https://www.thermofisher.com/
order/catalog/product/4475346).
Single MEK inhibitor treatments are very effective in pancreatic cancers
harboring the rare G12C mutation in KRAS, while combination therapies
can be effective in other subtypes
We analyzed the inhibitory effect of four frequently used MEK inhibitors. In our in vitro
model MiaPaCa2 (KRAS-G12C) showed a very high sensitivity to these inhibitors (Fig 2)
The KRAS wild type BxPC3 cell line showed moderate sensitivity while in case of Panc1
Fig 1. Next-generation sequencing analysis of pancreatic tumors. The mutations (nonsense, missense and frameshift) found in coding region of the
50 examined genes (rows) in pancreatic cancers. Samples (columns, N = 114) are arranged to emphasize coexistence of mutations. Germline mutations
found in KDR and KIT genes are marked with different color. Cell lines are indicated, to show the covered percentage of population.
https://doi.org/10.1371/journal.pone.0185687.g001
MEK inhibitors in pancreatic cancers
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(KRAS-G12D), all the MEK inhibitors proved to be absolutely ineffective. The lowest IC50
concentration was experienced when we treated MiaPaCa2 and BxPC3 cells with the drug tra-
metinib (Fig 2A). In order to increase efficiency, we first combined trametinib with an EGFR
inhibitor. Afatinib was much more effective in vitro than erlotinib, which is the FDA approved
drug in pancreatic cancer therapy (Fig 2A), therefore we used afatinib in combination with tra-
metinib. We could reach extreme low clinically relevant IC50 values and strong synergic effect
(CI: 0.11) in the KRAS wild type BxPC3 cell line. In case of Panc1 we observed only additive
effect and the IC50 concentrations were very high even in combinations. We also measured the
effect of trametinib in combination with the Akt inhibitor triciribine. (Fig 2B and 2C) This
combined application of the two drugs reduced the total applied dose in case of both cell lines
(BxPC3 and Panc1), and were synergistic in both cell lines particularly in Panc1. But the absolute
IC50 concentration of trametinib, was not under the clinically applicable limit in this cell line.
Fig 2. Results of viability assays on pancreatic cancer cell lines. (A) IC50 concentrations of MEK, EGFR and Akt inhibitors measured on MiaPaCa2,
BxPC3 and Panc1 cell lines (B) IC50 curves of MEK inhibitor (trametinib), Akt inhibitor (triciribine) and EGFR inhibitor (afatinib) treatment and MEK+Akt (1:1)
-/MEK+EGFR (1:1) inhibitor combination therapy on BxPC3 and Panc1 cell lines, curves were generated with GraphPad Prism version 7.00 for Mac (La
Jolla, CA, USA) software (C) IC50 concentration of different drug combinations applied in constant ratio (1:1) on BxPC3 and Panc1 cell lines and combination
indexes of the same drug combinations calculated with Calcusyn.
https://doi.org/10.1371/journal.pone.0185687.g002
MEK inhibitors in pancreatic cancers
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The activated signaling pathway and the inhibitory effect of trametinib
depends on the mutation present in KRAS and the expression level of
EGFR protein
Western blot analysis was used to examine the expression and phosphorylation of EGFR and
downstream ERK and Akt proteins in the three cell lines.
The MiaPaCa2 cell line showed extremely low level of EGFR expression and activation. Fur-
thermore the G12C mutant KRAS activated primarily the MEK/ERK pathway and the feed-
back activation of the EGFR-Akt pathway was expected to be less pronounced.
BxPC3 cells exhibited the highest EGFR expression and activity. While–probably due to the
wild type KRAS- ERK and Akt phosphorylation were in balance but the significant EGFR
activity could lead to the activation of the EGFR-Akt feedback loop upon MEK inhibition–as
assumed by the previously observed synergism of EGFR or Akt and MEK inhibitors in this cell
line.
Whereas Panc1 cells expressed high amount of EGFR, its activity wasn’t prominent. How-
ever, both expression and phosphorylation of Akt were remarkable in the KRAS G12D mutant
Panc1, in turn the activity of ERK was the lowest of all cell lines (Fig 3). This indicates that
G12D mutation in KRAS protein activates mainly the PI3K/Akt pathway rather than MEK/
ERK signaling, which is in line with the effective growth inhibition of the MEK+Akt inhibitor
combination in this cell line (Fig 2).
Next we analyzed the effect of trametinib on EGFR and Akt activity to corroborate the pres-
ence of a potential EGFR-feedback activation loop. In line with our hypothesis, trametinib
treated MiaPaCa2 cell line showed no increase in Akt activity when compared to the control
sample. However, the EGFR overexpressing BxPC3 cell line responded with an increased Akt
activity to trametinib treatment. While Panc1 showed remarkable baseline Akt activity both in
control cells and trametinib treated samples, further increase due to the treatment wasn’t
observed. These observations are in concert with only MiaPaCa2 being highly sensitive to sin-
gle MEK inhibitor treatment (Fig 4).
Fig 3. Protein expression and phosphorylation analysis of the used pancreatic cancer cell lines. (A)
EGFR and pY1068 EGRF, Akt and pS473 Akt, ERK1/2 and pT202/Y204 ERK were analyzed with SDS page/
Western blot method. (B) The expression and phosphorylation of all proteins were compared to the KRAS wild
type cell line, BxPC3. α-tubulin was used as loading control. (Original Western blot images: S1A and S1B
Fig).
https://doi.org/10.1371/journal.pone.0185687.g003
MEK inhibitors in pancreatic cancers
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Discussion
In our database of NGS profiles of 114 pancreatic cancer patients, the molecular subtype distri-
bution was similar to COSMIC (cancer.sanger.ac.uk) database [16]. KRAS and TP53 mutation
occurred frequently together, while CDKN2A and SMAD4 not. Only one of the tumors har-
bored mutations in all of the four genes. However 37% of tumors contained a (Q472H) muta-
tion in the KDR gene that was previously observed to be a germline mutation in melanomas,
non-small cell lung cancers and Ewing sarcomas in association with KDR phosphorylation or
microvessel density [17–19]. This mutation was also found in the BxPC3 cell line, but the anal-
ysis of its significance was not the objective of our work.
The examined cell lines represented the half of KRAS mutated pancreatic cancer cell types.
According to our NGS analysis, the most prevalent mutation in pancreatic cancers is G12D.
G12C is much less frequent in the Caucasian patients and may be associated with different bio-
logical characteristics as it was found to be associated with the worst prognosis in non-small
cell lung cancer (NSCLC) patients [20]. Interestingly, in Japanese population, G12C mutation
occurs more frequently: it was found in the 63% of pancreatic tumors [21].
Although in Caucasian population G12C mutation in pancreatic cancers seems to be less
important, their unfavorable prognosis and their different incidence in Japanese population
make it a major target in this type of cancer, too.
Besides, based on COSMIC database, G12C is the most frequent mutation at codon 12 in
lung cancers (39%) and also often occur in colon cancers (10,3%) [16].
In our in vitro pharmacological model, four MEK inhibitors, two EGFR inhibitors and one
Akt inhibitor were tested. We found that MEK inhibitors, particularly trametinib were the
most effective on MiaPaCa2 cell line. In this case, we could achieve significant growth inhibi-
tion with single MEK inhibitor treatment. This finding is consistent with the data of Pettazzoni
et al., where they found no synergism with the combination of selumetinib and erlotinib [11],
but their research did not focus on the molecular background of this phenomenon.
Erlotinib is the only targeted agent with FDA approval in pancreatic adenocarcinomas, but
Walters and colleagues found HER-2 to be also an important overexpressed protein in pancre-
atic cancers [22]. Afatinib is a pan-HER inhibitor and showed a greater inhibitory effect in
vitro, hence we used it in combination with the MEK inhibitor trametinib. Strong synergistic
effect was only revealed on the KRAS wild type BxPC3, while the combination of an Akt inhib-
itor (triciribine) with trametinib resulted in synergistic inhibitory effect on both BxPC3 and
Panc1 cell lines.
Fig 4. Response of pancreatic cancer cell lines to trametinib treatment. Total Akt level and Akt activation
status (pS473) were analyzed by Western blot. A representative blot and graphic evaluation of 3 independent
experiments. α-tubulin was used as loading control. (Original Western blot image: S1C Fig).
https://doi.org/10.1371/journal.pone.0185687.g004
MEK inhibitors in pancreatic cancers
PLOS ONE | https://doi.org/10.1371/journal.pone.0185687 September 28, 2017 8 / 13
In an isogenic colon cancer model, Modest et al. found different ERK activation associated
with certain KRAS subtypes [23]. The different pathway activation by KRAS subtypes has been
published by Ihle et al [24]. They found mainly MEK inhibitor sensitivity in case of KRAS G12C
NSCLC cell lines, while G12D mutant cell lines were rather sensitive to PI3K inhibition. Prahallad
et al. proved the feedback activation of EGFR when using BRAF inhibitors [10], which was also
observed in pancreatic cancers with MEK inhibitors [12]. It was also revealed that this loop had a
major role in cancer types with high EGFR expression [10]. However we observed the best effect
of MEK inhibitors (an extremely low IC50 concentration in case of trametinib) on MiaPaCa2 cell
line, which (apart from the lowest EGFR activation) had KRAS-G12C mutation. Bloomston et al
observed EGFR overexpression in 69% of pancreatic tumor tissues[25], which indicates that one
third of pancreatic cancers may have lower EGFR expression like MiaPaCa2.
The lower sensitivity of BxPC3 and Panc1 cells to MEK inhibition can be also explained by
their different EGFR protein expression and activation. The G12D mutant Panc1 cell line had
greater constitutive Akt activity, which could be caused directly by the constitutive activation
of the G12D mutant KRAS, so in this case, the combination with an EGFR inhibitor was inef-
fective. The BxPC3 cell line with wild type KRAS had equally active MEK/ERK and PI3K/Akt
Fig 5. The in vitro pancreatic cancer cell line model. This model is based on our protein expression and phosphorylation measurements and viability
assays. MiaPaCa2 cell line with KRAS G12C mutation and low EGFR level is highly sensitive to trametinib treatment, combination with other drugs is not
necessary and only increases drug toxicity. In case of BxPC3 cell line with wild type KRAS and high EGFR level/phosphorylation the feedback activation of
EGFR/PI3K/Akt to trametinib treatment has a great impact, therefore combination of the MEK inhibitor with EGFR or Akt inhibitor both results drug synergism.
Panc1 shows resistance to MEK inhibitors and the combination with the EGFR inhibitor afatinib does not decrease its IC50 concentration to an appropriate
level. Our model shows, that the presence of G12D mutation (which activates PI3K/Akt pathway) and the high expression of Akt protein both indicate the use
of MEK+Akt inhibitor combination.
https://doi.org/10.1371/journal.pone.0185687.g005
MEK inhibitors in pancreatic cancers
PLOS ONE | https://doi.org/10.1371/journal.pone.0185687 September 28, 2017 9 / 13
pathways, potentially dependent on the high EGFR activity. In this case, the feedback loop can
also have potentially a greater importance. In turn, both combinations (MEK+EGFR inhibi-
tion and MEK+Akt inhibition) raised synergistic effect in case of BxPC3. This hypothesis was
also confirmed by the analysis of Akt activity under trametinib effect.
The synergetic combination of MEK and PI3K/Akt or EGFR inhibitors (erlotinib and lapati-
nib) has been published before [11, 26, 27] and many ongoing clinical trials can be found with
these combination therapies. Although our study represents only three cell lines, the important
effect of KRAS G12D or G12C mutations and protein expression on sensitivity to MEK inhibi-
tors and their combinations were never observed before in case of pancreatic cancers (Fig 5).
Our work highlights that like NSCLCs, KRAS mutant pancreatic adenocarcinomas cannot
be regarded as a homogeneous group. Cell lines with G12C mutations may be more sensitive
to single MEK inhibitor treatment in multiple tumor types. As the intensified side effects
observed when using combination therapies [28] can limit their use, it is very important to
find a population, where monotherapy can be feasible. KRAS G12C mutation leads to the
worst prognosis observed in NSCLCs, too [20], so targeted therapies may have an emerging
role in these tumors. A study also revealed the better effect of selumetinib in case of G12C and
G12V mutant lung cancers [29]. KRAS G12C inhibitors also offer a very promising therapeutic
opportunity, but currently their use is only in research phase [30].
Moreover, it is also necessary to find the most beneficial combination therapy for other
molecular subtypes. Based on our result, combination of low concentrations of EGFR inhibi-
tors and MEK inhibitors may be clinically relevant in EGFR expressing KRAS wild type pan-
creatic cancers, which may represent 23% of pancreatic cancers, in addition to the 2% of G12C
KRAS mutants who may respond to MEK inhibition alone. In the case of G12D KRAS mutant
cancers, Akt inhibitors may sensitize to the MEK inhibitors but it seems we will need better
compounds to be successful in the clinical setting.
It also has to be noted that patients with different KRAS status and protein expression can
have a benefit from different combination therapies. G12R and G12V mutations are also
important and frequent, but their role was not investigated in this study. Further, the signifi-
cance of other parallel driver alterations in other molecular subtypes—which were confirmed
wild type in the investigated subtypes–will have to be investigated. Based on our results, we
propose the combination of NGS sequence data with EGFR expression analysis in order to
find the most beneficial treatment in pancreatic cancers.
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S1 Fig. Original Western blot images. Figure A, B and C represent the original Western blot
images used in Fig 3. and Fig 4.
(TIF)
Author Contributions
Conceptualization: Dia´na Brauswetter, Bianka Gurbi, Istva´n Peta´k.
Data curation: Dia´na Brauswetter, Bianka Gurbi, Edit Va´rkondi, Istva´n Peta´k.
Formal analysis: Dia´na Brauswetter, Bianka Gurbi, Attila Varga, Edit Va´rkondi.
Funding acquisition: Istva´n Peta´k.
Investigation: Dia´na Brauswetter, Bianka Gurbi, Attila Varga, Edit Va´rkondi, Istva´n Peta´k.
Methodology: Dia´na Brauswetter, Bianka Gurbi, Attila Varga, Edit Va´rkondi, Istva´n Peta´k.
MEK inhibitors in pancreatic cancers
PLOS ONE | https://doi.org/10.1371/journal.pone.0185687 September 28, 2017 10 / 13
Project administration: Dia´na Brauswetter, Istva´n Peta´k.
Resources: Ga´bor Ba´nhegyi, Istva´n Peta´k.
Software: Edit Va´rkondi, Orsolya Fa´bia´n, Istva´n Peta´k.
Supervision: Richa´rd Schwab, Ga´bor Ba´nhegyi, Gyo¨rgy Ke´ri, Istva´n Va´lyi-Nagy, Istva´n Peta´k.
Validation: Istva´n Peta´k.
Visualization: Dia´na Brauswetter, Attila Varga, Istva´n Peta´k.
Writing – original draft: Dia´na Brauswetter, Bianka Gurbi, Attila Varga, Edit Va´rkondi, Rich-
a´rd Schwab, Ga´bor Ba´nhegyi, Gyo¨rgy Ke´ri, Istva´n Va´lyi-Nagy, Istva´n Peta´k.
Writing – review & editing: Dia´na Brauswetter, Attila Varga, Ga´bor Ba´nhegyi, Orsolya
Fa´bia´n, Gyo¨rgy Ke´ri, Istva´n Va´lyi-Nagy, Istva´n Peta´k.
References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a
cancer journal for clinicians. 2015; 65(2):87–108. Epub 2015/02/06. https://doi.org/10.3322/caac.21262
PMID: 25651787.
2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer inci-
dence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United
States. Cancer research. 2014; 74(11):2913–21. Epub 2014/05/21. https://doi.org/10.1158/0008-5472.
CAN-14-0155 PMID: 24840647.
3. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, et al. Recent progress in pan-
creatic cancer. CA: a cancer journal for clinicians. 2013; 63(5):318–48. Epub 2013/07/17. https://doi.
org/10.3322/caac.21190 PMID: 23856911; PubMed Central PMCID: PMC3769458.
4. Heestand GM, Kurzrock R. Molecular landscape of pancreatic cancer: implications for current clinical
trials. Oncotarget. 2015; 6(7):4553–61. Epub 2015/02/26. https://doi.org/10.18632/oncotarget.2972
PMID: 25714017; PubMed Central PMCID: PMCPmc4467098.
5. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in
human pancreatic cancers revealed by global genomic analyses. Science (New York, NY). 2008; 321
(5897):1801–6. Epub 2008/09/06. https://doi.org/10.1126/science.1164368 PMID: 18772397; PubMed
Central PMCID: PMC2848990.
6. Makohon-Moore A, Iacobuzio-Donahue CA. Pancreatic cancer biology and genetics from an evolution-
ary perspective. Nature reviews Cancer. 2016; 16(9):553–65. Epub 2016/07/23. https://doi.org/10.
1038/nrc.2016.66 PMID: 27444064.
7. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the
mutational landscape of pancreatic cancer. Nature. 2015; 518(7540):495–501. Epub 2015/02/27.
https://doi.org/10.1038/nature14169 PMID: 25719666; PubMed Central PMCID: PMCPmc4523082.
8. Infante JR, Somer BG, Park JO, Li CP, Scheulen ME, Kasubhai SM, et al. A randomised, double-blind,
placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients
with untreated metastatic adenocarcinoma of the pancreas. European journal of cancer. 2014; 50
(12):2072–81. Epub 2014/06/12. https://doi.org/10.1016/j.ejca.2014.04.024 PMID: 24915778.
9. Bodoky G, Timcheva C, Spigel DR, La Stella PJ, Ciuleanu TE, Pover G, et al. A phase II open-label ran-
domized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus
capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemci-
tabine therapy. Investigational new drugs. 2012; 30(3):1216–23. https://doi.org/10.1007/s10637-011-
9687-4 PMID: 21594619.
10. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of
colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012; 483
(7387):100–3. https://doi.org/10.1038/nature10868 PMID: 22281684.
11. Pettazzoni P, Viale A, Shah P, Carugo A, Ying H, Wang H, et al. Genetic events that limit the efficacy of
MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer
research. 2015; 75(6):1091–101. Epub 2015/03/05. https://doi.org/10.1158/0008-5472.CAN-14-1854
PMID: 25736685; PubMed Central PMCID: PMCPmc4446709.
12. Mirzoeva OK, Collisson EA, Schaefer PM, Hann B, Hom YK, Ko AH, et al. Subtype-specific MEK-PI3
kinase feedback as a therapeutic target in pancreatic adenocarcinoma. Molecular cancer therapeutics.
MEK inhibitors in pancreatic cancers
PLOS ONE | https://doi.org/10.1371/journal.pone.0185687 September 28, 2017 11 / 13
2013; 12(10):2213–25. https://doi.org/10.1158/1535-7163.MCT-13-0104 PMID: 23918833; PubMed
Central PMCID: PMCPMC3800201.
13. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method.
Cancer research. 2010; 70(2):440–6. https://doi.org/10.1158/0008-5472.CAN-09-1947 PMID:
20068163.
14. Manchado E, Weissmueller S, Morris JPt, Chen CC, Wullenkord R, Lujambio A, et al. A combinatorial
strategy for treating KRAS-mutant lung cancer. Nature. 2016; 534(7609):647–51. https://doi.org/10.
1038/nature18600 PMID: 27338794; PubMed Central PMCID: PMCPMC4939262.
15. Mullendore ME, Koorstra JB, Li YM, Offerhaus GJ, Fan X, Henderson CM, et al. Ligand-dependent
Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clinical can-
cer research: an official journal of the American Association for Cancer Research. 2009; 15(7):2291–
301. https://doi.org/10.1158/1078-0432.CCR-08-2004 PMID: 19258443; PubMed Central PMCID:
PMCPMC2711441.
16. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the
world’s knowledge of somatic mutations in human cancer. Nucleic acids research. 2015; 43(Database
issue):D805–11. https://doi.org/10.1093/nar/gku1075 PMID: 25355519.
17. Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson EE, et al. Novel functional germline variants
in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung can-
cer. Clinical cancer research: an official journal of the American Association for Cancer Research.
2011; 17(16):5257–67. https://doi.org/10.1158/1078-0432.CCR-11-0379 PMID: 21712447; PubMed
Central PMCID: PMCPMC3156871.
18. Zhang N, Liu H, Yue G, Zhang Y, You J, Wang H. Molecular Heterogeneity of Ewing Sarcoma as
Detected by Ion Torrent Sequencing. PloS one. 2016; 11(4):e0153546. https://doi.org/10.1371/journal.
pone.0153546 PMID: 27077911; PubMed Central PMCID: PMCPMC4831808.
19. Silva IP, Salhi A, Giles KM, Vogelsang M, Han SW, Ismaili N, et al. Identification of a Novel Pathogenic
Germline KDR Variant in Melanoma. Clinical cancer research: an official journal of the American Associ-
ation for Cancer Research. 2016; 22(10):2377–85. https://doi.org/10.1158/1078-0432.CCR-15-1811
PMID: 26631613; PubMed Central PMCID: PMCPMC4867268.
20. Nadal E, Beer DG, Ramnath N. KRAS-G12C mutation is associated with poor outcome in surgically
resected lung adenocarcinoma. Journal of thoracic oncology: official publication of the International
Association for the Study of Lung Cancer. 2015; 10(2):e9–10. Epub 2015/01/23. https://doi.org/10.
1097/jto.0000000000000438 PMID: 25611236; PubMed Central PMCID: PMCPmc4344375.
21. Zhou L, Baba Y, Kitano Y, Miyake K, Zhang X, Yamamura K, et al. KRAS, BRAF, and PIK3CA muta-
tions, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature
review. Medical oncology (Northwood, London, England). 2016; 33(4):32. Epub 2016/03/02. https://doi.
org/10.1007/s12032-016-0745-9 PMID: 26927447.
22. Walters DM, Lindberg JM, Adair SJ, Newhook TE, Cowan CR, Stokes JB, et al. Inhibition of the growth
of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by com-
bined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib. Neoplasia (New
York, NY). 2013; 15(2):143–55. Epub 2013/02/27. PMID: 23441129; PubMed Central PMCID:
PMCPmc3579317.
23. Modest DP, Camaj P, Heinemann V, Schwarz B, Jung A, Laubender RP, et al. KRAS allel-specific activ-
ity of sunitinib in an isogenic disease model of colorectal cancer. Journal of cancer research and clinical
oncology. 2013; 139(6):953–61. Epub 2013/03/05. https://doi.org/10.1007/s00432-013-1401-9 PMID:
23455880.
24. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, et al. Effect of KRAS oncogene sub-
stitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012;
104(3):228–39. Epub 2012/01/17. https://doi.org/10.1093/jnci/djr523 PMID: 22247021; PubMed Cen-
tral PMCID: PMC3274509.
25. Bloomston M, Bhardwaj A, Ellison EC, Frankel WL. Epidermal growth factor receptor expression in pan-
creatic carcinoma using tissue microarray technique. Dig Surg. 2006; 23(1–2):74–9. https://doi.org/10.
1159/000093497 PMID: 16717472.
26. Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, et al. A central role for RAF—>MEK—
>ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer discovery. 2012; 2
(8):685–93. Epub 2012/05/26. https://doi.org/10.1158/2159-8290.CD-11-0347 PMID: 22628411;
PubMed Central PMCID: PMCPmc3425446.
27. Dumble M, Crouthamel MC, Zhang SY, Schaber M, Levy D, Robell K, et al. Discovery of novel AKT
inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PloS one. 2014; 9(6):
e100880. Epub 2014/07/01. https://doi.org/10.1371/journal.pone.0100880 PMID: 24978597; PubMed
Central PMCID: PMCPmc4076210.
MEK inhibitors in pancreatic cancers
PLOS ONE | https://doi.org/10.1371/journal.pone.0185687 September 28, 2017 12 / 13
28. Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, et al. A phase Ib dose-
escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2
inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clinical cancer
research: an official journal of the American Association for Cancer Research. 2015; 21(4):730–8. Epub
2014/12/17. https://doi.org/10.1158/1078-0432.ccr-14-1814 PMID: 25500057.
29. Janne PA, Smith I, McWalter G, Mann H, Dougherty B, Walker J, et al. Impact of KRAS codon subtypes
from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell
lung cancer. British journal of cancer. 2015; 113(2):199–203. Epub 2015/07/01. https://doi.org/10.1038/
bjc.2015.215 PMID: 26125448; PubMed Central PMCID: PMCPmc4506393.
30. Lito P, Solomon M, Li LS, Hansen R, Rosen N. Allele-specific inhibitors inactivate mutant KRAS G12C
by a trapping mechanism. Science (New York, NY). 2016; 351(6273):604–8. https://doi.org/10.1126/
science.aad6204 PMID: 26841430; PubMed Central PMCID: PMCPMC4955282.
MEK inhibitors in pancreatic cancers
PLOS ONE | https://doi.org/10.1371/journal.pone.0185687 September 28, 2017 13 / 13
